Search

Author/Creator Hofmann, M.H.

1. Combination of the novel BET inhibitor BI 894999 with CDK9 inhibition suggests a promising regimen for the treatment of AML. (December 2016)

Authors:
Tontsch-Grunt, U.; Savarese, F.; Baum, A.; Scharn, D.; Gerlach, D.; Hofmann, M.H.; Popow, J.; Schweifer, N.; Engelhardt, H.; Musa, H.; Lee, C.P.; Munzert, G.M.; Kraut, N.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S89
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. MEKi-based combination strategies for targeting KRAS-driven cancer. (October 2022)

Authors:
Kostyrko, K.; Hinkel, M.; Traexler, P.E.; Arnold, D.; Melo-Zainzinger, G.; Gerlach, D.; Ruzicka, R.; Jacob, R.; Baum, A.; Lu, H.; Vellano, C.P.; Marszalek, J.R.; Heffernan, T.P.; Tontsch-Grunt, U.; Hofmann, M.H.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S54
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search